Anne F. Schott - Concepedia

Author

Anne F. Schott

Also Known As

A SCHOTT, A Schott, A. F. SCHOTT, A. F. Schott, A. Schott, A.F Schott, A.F. Schott, Anne F Schott, Anne F. Schott, Anne Schott

181

Publications

11.5K

Citations

H-Index

Concepts

All Affiliations

University of Michigan Michigan Center for Translational Pathology Dana-Farber Cancer Institute Johns Hopkins University The University of Texas MD Anderson Cancer Center

About

Anne F. Schott is an author at University of Michigan specializing in medicine, breast cancer, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	21	27	6.9K
2	Health Sciences	9	9	4.5K
3	Public Health	2	2	57
4	Engineering	1	1	10
5	Allergy	1	1	29

Anne F. Schott

Publications

11.1K

Citations

H-Index

Page 1

	Year	Citations
ALDH1 Is a Marker of Normal and Malignant Human Mammary Stem Cells and a Predictor of Poor Clinical Outcome Christophe Ginestier, Min Hee Hur, Emmanuelle Charafe‐Jauffret, Cell stem cell Lineage PlasticityBreast OncologyMedicinePoor Clinical OutcomeMammary Gland	2007	4K
Activating ESR1 mutations in hormone-resistant metastatic breast cancer Dan R. Robinson, Yi-Mi Wu, Pankaj Vats, Nature Genetics Breast OncologyMedicineBreast CancerEsr1 MutationsCancer Genetics	2013	1.1K
Cancer cells induce metastasis-supporting neutrophil extracellular DNA traps Juwon Park, Robert W. Wysocki, Zohreh Amoozgar, Science Translational Medicine	2016	953
Circulating Tumor Cells and Response to Chemotherapy in Metastatic Breast Cancer: SWOG S0500 Jeffrey B. Smerage, William E. Barlow, Gabriel N. Hortobágyi, Journal of Clinical Oncology	2014	629
Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer Charles E. Geyer, Judy E. Garber, Richard D. Gelber, Annals of Oncology Breast OncologyOverall SurvivalMedicinePathologyGermline Pathogenic Variants	2022	404
Preclinical and Clinical Studies of Gamma Secretase Inhibitors with Docetaxel on Human Breast Tumors Anne F. Schott, Melissa D. Landis, Gabriela Dontu, Clinical Cancer Research	2013	261
Phase Ib Pilot Study to Evaluate Reparixin in Combination with Weekly Paclitaxel in Patients with HER-2–Negative Metastatic Breast Cancer Anne F. Schott, Lori J. Goldstein, Massimo Cristofanilli, Clinical Cancer Research	2017	234
The effect of an individual's cytochrome CYP3A4 activity on docetaxel clearance. Jo Ann Hirth, Paul B. Watkins, Myla Strawderman, PubMed PharmacotherapyExperimental PharmacologyPhysiologically-based Pharmacokinetic ModelingTranslational PharmacologyMolecular Pharmacology	2000	202
<i>ESR1</i> Mutations in Circulating Plasma Tumor DNA from Metastatic Breast Cancer Patients David Chu, Costanza Paoletti, Christina L. Gersch, Clinical Cancer Research	2015	173
Sentinel Lymph Node Biopsy Performed After Neoadjuvant Chemotherapy is Accurate in Patients with Documented Node-Positive Breast Cancer at Presentation Erika A. Newman, Michael S. Sabel, Alexis V. Nees, Annals of Surgical Oncology Surgical OncologyBreast OncologyNeoadjuvant ChemotherapyCancer DetectionMedicine	2007	163

Page 1